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Abstract
Background:  Plasma lipases and lipid transfer proteins are involved in the generation and
speciation of high density lipoproteins. In this study we have examined the influence of plasma
lipases and lipid transfer protein activities on the transfer of free cholesterol (FC) and phospholipids
(PL) from lipid emulsion to human, rat and mouse lipoproteins. The effect of the lipases was verified
by incubation of labeled (3H-FC,14C-PL) triglyceride rich emulsion with human plasma (control,
post-heparin and post-heparin plus lipase inhibitor), rat plasma (control and post-heparin) and by
the injection of the labeled lipid emulsion into control and heparinized functionally hepatectomized
rats.
Results:  In vitro, the lipase enriched plasma stimulated significantly the transfer of 14C-PL from
emulsion to high density lipoprotein (p<0.001) but did not modify the transfer of 3H-FC. In
hepatectomized rats, heparin stimulation of intravascular lipolysis increased the plasma removal of
14C-PL and the amount of 14C-PL found in the low density lipoprotein density fraction but not in
the high density lipoprotein density fraction. The in vitro and in vivo experiments showed that free
cholesterol and phospholipids were transferred from lipid emulsion to plasma lipoproteins
independently from each other. The incubation of human plasma, control and control plus
monoclonal antibody anti-cholesteryl ester transfer protein (CETP), with 14C-PL emulsion showed
that CETP increases 14C-PL transfer to human HDL, since its partial inhibition by the anti-CETP
antibody reduced significantly the 14C-PL transfer (p<0.05). However, comparing the
nontransgenic (no CETP activity) with the CETP transgenic mouse plasma, no effect of CETP on
the 14C-PL distribution in mice lipoproteins was observed.
Conclusions:  It is concluded that: 1-intravascular lipases stimulate phospholipid transfer protein
mediated phospholipid transfer, but not free cholesterol, from triglyceride rich particles to human
high density lipoproteins and rat low density lipoproteins and high density lipoproteins; 2-free
cholesterol and phospholipids are transferred from triglyceride rich particles to plasma
lipoproteins by distinct mechanisms, and 3 - CETP also contributes to phospholipid transfer activity
in human plasma but not in transgenic mice plasma, a species which has high levels of the specific
phospholipid transfer protein activity.
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Background
There have been plenty of epidemiological, clinical and
experimental evidence that plasma high density lipopro-
teins levels are inversely correlated with the risk of
atherosclerosis [1,2]. The contribution of enzymes and
proteins associated with HDL to its process of generation
and maturation have been extensively studied, both in
vitro and in vivo.
The plasma cholesteryl ester transfer protein (CETP)
modulates HDL levels and composition. It mediates the
transfer of cholesteryl ester (CE) from HDL to triglycer-
ide (TG) rich lipoproteins (LP), while TG is transferred in
the opposite direction, to HDL. One way CE transfer
from HDL to LDL may also occur [3]. CETP also pro-
motes phospholipid (PL) transfer to human HDL [4,5,6].
CETP activity has been directly correlated with LDL cho-
lesterol levels and inversely correlated with HDL choles-
terol levels in human plasma [3,7].
PLTP, a specific phospholipid transfer protein, has been
identified in human plasma [8,9] and in plasma of other
vertebrate species [10]. It promotes the PL transfer from
VLDL to HDL [11]. In addition to PL, PLTP transfers free
cholesterol (FC) from PL/FC vesicles to HDL, although
with a low efficiency [12]. Both, CETP and PLTP, can
promote HDL remodelling. While CETP, together with
hepatic lipoprotein lipase, stimulates the generation of
small alpha-HDL, PLTP favours the emergence of large
alpha-HDL particles [13]. Significantly higher levels of
HDL-cholesterol were observed in human PLTP trans-
genic mice [14]. Furthermore, overexpression of human
PLTP produced by recombinant adenovirus injection
into mice, resulted in increased levels of prebeta-HDL,
increased fractional catabolic rate and liver uptake of CE
and PL from HDL [15].
After intravascular hydrolysis of TG rich LP by lipopro-
tein lipase (LPL), surface remnant components such as
FC, PL and apoproteins may provide substrates for gen-
eration or modification of plasma HDL. Net transfer of
PL and FC from chylomicrons and VLDL to HDL has pre-
viously been demonstrated in rats [16,17] and in human
plasma after a fat meal [18,19] or during lipolysis [11].
The contribution of the lipolysed LP components to HDL
formation has been reinforced by several studies where
the activity of the enzyme lipoprotein lipase LPL was
shown to correlate with HDL cholesterol levels in human
plasma [20,21,22]. However, changes in the HDL-cho-
lesterol concentration have not been observed in mice
overexpressing LPL [23] or in LPL heterozygous knock-
out mice [24].
The metabolism of HDL in rats and mice differs signifi-
cantly from that in humans. Part of the species differenc-
es observed in mice and in rats may result from their
high levels of circulating lipases [25,26], lack of CETP
[27] and high levels of PLTP [10]. Clee et al. [28] have
shown that, in double transgenic mice overexpressing
LPL and CETP, HDL cholesterol levels were significantly
influenced by the LPL activity while no such correlation
was observed in the absence of CETP expression.
In this study we have further evaluated the influence of
plasma lipases and CETP on the free cholesterol and
phospholipid transfer from triglyceride rich lipid emul-
sion similar to chylomicrons [29,30] to human, rat and
mouse lipoproteins, in vitro and in vivo.
Results
The influence of the intravascular lipase activity on the
phospholipids (PL) and free cholesterol (FC) transfer
from lipid emulsion (EM) to plasma lipoproteins was
evaluated in human control plasma, in lipase-enriched
post-heparin plasma and in post-heparin plasma con-
taining a lipase inhibitor, tetrahydrolipstatin (THL) [34].
PL transfer was determined after 30 minutes of incuba-
tion because Tall et al. [8] have demonstrated that PL net
transfer reaches the maximum after this incubation peri-
od. The post-heparin plasma lipoprotein lipase (LPL)
and hepatic lipoprotein lipase (HL) activities were 2527
± 1353 and 3747 ± 2116 nmol of fatty acid/ml/h, respec-
tively. The control and post-heparin + THL plasmas had
no detectable lipase activity, showing that 2 mM THL
completely inhibited the activities of the lipases present
in the post-heparin plasma. Table 1 shows that 14C-PL
was preferentially transferred to HDL (p<0.001) while
3H-FC was equally distributed to LDL and HDL fractions
under all 3 plasma conditions. The transfer of 14C-PL
from EM to HDL was significantly stimulated (+60%) by
the increase in the lipases' activities in the post-heparin
plasma (p<0.001). This stimulation of the PL transfer
was abolished in the presence of THL (p<0.01). Consid-
ering that HL also has phospholipase activity, the integ-
rity of the phospholipid transferred to HDL was checked
by thin layer chromatography. Ninety eight % of the 14C-
PL was recovered in the PL band and no radioactivity
was detected in the fatty acid bands. The proportion of
3H-FC and 14C-PL found in HDL (0.4) was different from
that found in LDL (2.3) or in the EM (1.5), which sug-
gests that these components of the EM were independ-
ently transferred to the LP fractions and not as a surface
unit detached from the lipolysed EM.
The effect of plasma lipases on the PL transfer to HDL
was also verified by incubating labeled EM with plasma
from control and heparinized rats. Figure 1 shows the
14C-PL distribution in the LP fractions at zero (ice) or af-
ter 30 minutes at 37°C. In the control rat plasma (Fig. 1,
upper panel) at time zero, the distribution of 14C-PL was
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60, 13, 22 and 6% for VLDL, LDL, HDL and a fraction
smaller than HDL (<HDL), respectively, while after 30
minutes at 37°C, the observed distribution was 22, 14, 57
and 8% for VLDL, LDL, HDL and fraction <HDL, respec-
tively. It is interesting that PL transfer to HDL can be ob-
served even at time zero. This may represent the
combination of the spontaneous and facilitated transfer
that occurs during and even after loading the reaction
mixture to the FPLC column run at room temperature.
Furthermore, rat plasma contains circulating lipases
[25,26] that could be stimulating PL transfer in the con-
trol plasma. In the rat post-heparin plasma (Fig. 1, lower
panel), the 14C-PL transfer was so much accelerated that
the distributions at zero and after 30 minutes of incuba-
tion at 37°C were almost identical, that is, 12, 29.5, 32.5
and 26.5% at zero and 7, 31, 29.5 and 32.5% at 37°C for
Figure 1
Influence of plasma lipases on the distribution of the 14C-PL from lipid emulsions into rat plasma lipoproteins. Control (upper
panel) and heparin treated (lower panel) rat plasmas were incubated with lipid emulsion labeled with 14C-phospholipids (PL) at
zero (on ice) (open triangles) or for 30 minutes at 37°C (closed triangles), and fractionated by fast protein liquid chromatogra-
phy. Cholesterol mass in each fraction (O.D.500 nm) is shown in the dotted line profile.
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VLDL, LDL, HDL and fraction <HDL, respectively. HDL
and the fraction smaller than HDL together accounted
for 59 to 62% of the 14C-PL. Thus, comparing the PL moi-
ety that remained in the emulsion fraction in the control
at 37°C (Fig 1 upper, 22%) with the post-heparin plasma
at 37°C (Fig 1 lower, 7%), we conclude that PL transfer to
LDL and HDL fractions is highly stimulated by the en-
richment of the rat plasma with the vascular lipases. We
did not investigate the chemical nature of the fraction
smaller than HDL but we speculate that it derives from
HDL phospholipids or from the emulsion surface itself,
and might be lysophospholipids/albumin or phospholip-
ids/apo AI complexes.
In an attempt to evaluate the PL and FC transfer to HDL
in a biological system, we injected the radioactive EM
(3H-PL/14C -FC) into anesthetised functionally hepatec-
tomized rats treated with saline (control) or heparin
(LPL stimulated). The liver exclusion maneuver was
done in order to minimize the differences in the resi-
dence time of the emulsion particles in the circulation of
the control and LPL stimulated rats. The hepatectomy ef-
ficacy was verified by the amount of 3H-PL found in the
livers at the end of the experiments; that was 1% and 3%
of the injected dose in control and heparinized animals,
respectively. There was a lower recovery of the labeled
PL in the plasma of the heparinized animals (∼ 50%)
than in control rats (∼ 90%). This suggests that the
heparin stimulated lipolysis increased the plasma re-
moval of PL by peripheral tissues. Table 2 shows the dis-
tribution of 3H-PL and 14C-FC from the EM into the
plasma LP of control and heparinized hepatectomized
rats. When intravascular lipolysis was stimulated by
heparin, there was a 50% reduction of the 3H-PL content
in the chylomicron (CM) + VLDL fraction (d<1.006) and
a parallel increase in the LDL fraction that also includes
remnant particles (d= 1.006 to 1.063). No significant dif-
ference was observed in the amount of 3H-PL found in
the HDL fraction of control and heparinized hepatect-
omized rats. A similar result was observed in relation to
the 14C-FC distribution, i.e., a reduction trend of 14C-FC
in the CM+VLDL fraction (non significant) and a signif-
icant increase of 14C-FC transfer to the LDL fraction.
However, in both cases, control and heparinized ani-
mals, the ratio 14C-FC/3H-PL differs markedly in the
three LP fractions (Table 2). This indicates that, in vivo,
the redistribution of the two emulsion surface lipids is
independent one from another.
In order to verify the influence of CETP in the PL transfer
to HDL, labeled emulsion was incubated with human
plasma in the presence and absence of monoclonal anti-
body against CETP (TP2) and with plasma from CETP
transgenic and non-transgenic mice. The CETP activity
in these plasmas were 38 and 16% of cholesteryl ester
transfer (4 h assay) respectively for human plasma with-
out and with TP2, and 5 and 20% of cholesteryl ester
transfer (2 h assay), respectively for nontransgenic and
human CETP transgenic mice plasma. Table 3 shows
that 14C-PL transfer from lipid emulsion to human HDL
was reduced 40% (p<0.005) when CETP activity was in-
hibited 58%, indicating that CETP has PL transfer activ-
ity as previously reported [5]. However, the 14C-PL
distribution in mice LP after incubation with the 14C-PL
EM was almost identical for CETP transgenic and non-
transgenic mice plasma (Fig. 2). The human CETP ex-
pressed in these mice might not efficiently interact with
the endogenous mice HDL. To check this possibility an
exogenous assay was performed using human HDL (240
ug cholesterol) as PL acceptor and minimal amounts of
Table 1: Influence of plasma lipases on the 3H-free cholesterol (FC) and 14C-phospholipid (PL) transfer from lipid emulsions to the hu-
man plasma lipoproteins.
Fractions Control Post-heparin Post-heparin + THL
3H-FC 14C-PL 3H-FC 14C-PL 3H-FC 14C-PL
LDL 15 7 21 7 20 6
(2-35) (3-49) (15-26) (2-13) (17-34) (1-12)
HDL 13 31a 18 50a,b 15 39a,c
(7-28) (18-47) (12-36) (35-68) (8-33) (23-48)
Percent transfer of 3H-FC and 14C-PL from lipid emulsion to LDL and HDL obtained from fasting human plasma control, post-heparin with and with-
out addition of a lipase inhibitor, tetrahydrolipstatin (THL) incubated for 30 minutes at zero (ice) and at 37°C. Plasma lipoproteins were fractionated 
by FPLC. Percent transfer was calculated as the difference between values obtained at 37°C and 0°C. Results are expressed as median (range), n=12. 
Mann-Whitney test: a: p< 0.001 (HDL vs. LDL) ; b: p<0.001 (post-heparin vs. control) and c: p<0.01 (post-heparin vs. post-heparin+THL).
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CETP transgenic and non-transgenic mice plasma (50
ul) as sources of CETP and of PLTP. Results obtained
(data not shown) were identical to those of the endog-
enous assay (fig. 2). Therefore, human CETP in trans-
genic mice plasma does not contribute to PL transfer to
either mice or human HDL.
Discussion
Several studies, using different experimental approach-
es, have shown that the transfer of surface components
of TG-rich lipoproteins during their intravascular me-
tabolism is important to determine both level and chem-
Figure 2
Influence of CETP on the distribution of the 14C-PL from lipid emulsions into mice plasma lipoproteins. Control non-transgenic
(upper panel) and CETP transgenic (lower panel) mice plasmas were incubated with lipid emulsion labeled with 14C-phospholi-
pids (PL) at zero (on ice) (open triangles) or for 30 minutes at 37°C (closed triangles), and fractionated by fast protein liquid
chromatography. Cholesterol mass in each fraction (O.D.500 nm) is shown in the dotted line profile.
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ical composition of the HDL subfractions. The present
work has confirmed and extended previous observations
showing that human and rat plasma lipoprotein lipases
stimulate PLTP mediated PL transfer from TG-rich par-
ticles to HDL but do not influence the FC transfer proc-
ess. Some of the previous studies [11,35,36,37,38] that
used purified exogenous lipases in in vitro incubations
with isolated LP displayed a potent stimulation of the PL
transfer to HDL. In order to prepare a model that would
mirror a physiological system more closely, we have used
whole plasma and maximal endogenous lipases activity
through heparin administration in vivo as well as in vit-
ro. It is possible that other proteins released by heparin
in the vascular bed may have played a role in stimulating
PL transfer. The role of circulating lipases was confirmed
through the use of a lipase inhibitor (THL), which abol-
ished the stimulating effect of lipase-enriched plasma on
the PL transfer to HDL (Tab. 1). According to these ex-
periments it is likely that during fasting state, where no
circulating lipases are detectable, all PL transfer results
from the action of the lipid transfer proteins, PLTP and
CETP, while in a post-prandial state, when lipases ex-
pectedly are more active, the PL transfer to HDL could be
raised by 60% or more due to a greater substrate supply .
Noteworthy the in vitro PL transfer to HDL in the basal
plasmas of rat (fig. 1, 82%) and mouse (fig. 2, 57%) was
higher than in the human's (Tab. 1, 31%) and could be as-
cribed to the high levels of circulating lipases [26,39,40]
and PLTP [10] found in those species. This could also ex-
plain the positive correlation between the lipoprotein li-
pase activity and HDL concentration in human plasma
[20,21,22] but not in mice with genetically modified ex-
pression of LPL [23,24,28].
The in vivo studies showed that the EM PL transfer to
HDL did not differ in control and in LPL stimulated
(heparin treated) hepatectomized rats. Instead, the LDL
density fraction was PL enriched in the heparinized ani-
mals. This could be explained by several and not exclu-
sive possibilities. First, the lipolysis stimulation by
heparin generates more remnants of the EM that would
float in the same density range as LDL (1.006 - 1.063).
Second, the rat plasma fraction smaller than HDL that
appeared in the in vitro incubations with post-heparin
plasma (Fig. 1) could also occur in vivo and float in the
same density range as LDL (1.006 -1.063). In this regard,
O'Meara et. al. [41] had shown that small HDL particles
from heparinized hypertriglyceridemic subjects, identi-
fied in non-denaturing gel electrophoresis and by elec-
tron microscopy, floated after ultracentrifugation in a
Table 2: Influence of plasma lipases on the distribution of 14C-free cholesterol (FC) and 3H-phospholipid (PL) from lipid emulsions to 
plasma lipoproteins of hepatectomized rats in vivo.
Fractions Control Heparinized
14C-FC 3H-PL 14C-FC 3H-PL
CM+ VLDL 61 36 47 16a
(53 - 74) (27 - 61) (43 - 55) (14 - 22)
LDL + remnants 20 22 34b 38c
(11 - 24) (10 - 26) (29 - 38) (33 - 42)
HDL 19 42 18 46
(15 - 23) (29 - 47) (14 - 22) (40 - 51)
Percent distribution of 14C-FC and 3H-PL from lipid emulsion to VLDL, LDL and HDL plasma fractions from anesthetized hepatectomized rats treat-
ed with saline (control) or heparin after 30 minutes of an intra-arterial injection of the labeled emulsion. Lipoprotein fractions were obtained by 
ultracentrifugation. Results are expressed as median (range), n=4. Mann-Whitney test for heparin vs. control comparisons: a: 3H-PL - CM+VLDL, p 
< 0.03; b: 14C-FC - LDL, p < 0.03; c: 3H-PL - LDL, p < 0.03.
Table 3: Influence of CETP on the 14C-phospholipid (PL) transfer 
from lipid emulsions to the human plasma lipoproteins.
Fractions Control +TP2
LDL 4 (0 - 6) 0 (-5 - 1)
HDL 30a (26 - 38) 18a,b (16 - 27)
Percent transfer of 14C-PL from lipid emulsion to LDL and HDL ob-
tained from fasting human plasma without (control) and with CETP 
monoclonal antibody, TP2, incubated for 30 minutes at zero (ice) and 
at 37°C. Plasma lipoproteins were fractionated by FPLC. Percent trans-
fer was calculated as the difference between values obtained at 37°C 
and 0°C. Results are expressed as median (range), n=6. Mann-Whitney 
test: a: p<0.001 (HDL vs. LDL), b: p<0.05 (TP2 vs. control).
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less dense range. Those authors had considered it an ab-
errant result of the ultracentrifugation technique. Third,
the diminished availability of PL donor particles in the
plasma of the heparinized rats (yield of 50%) as com-
pared to control rats (yield of 90%) would be responsible
for the apparent lack of stimulation of the PL transfer to
the HDL fraction. Finally, other in vivo metabolic fates of
PL would compete for the transfer process to plasma
HDL particles in LPL stimulated animals.
The emulsion FC transfer to HDL was about 40% that of
PL in both, in vitro (Tab. 1) and in vivo (Tab. 2) studies
and it was not influenced by increased rate of intravascu-
lar lipolysis. These results suggest that the FC transfer is
a slower, probably passive, process distinct from the fa-
cilitated PL transfer mechanism [8,9]. Also, these results
challenge the possibility that new HDL particles are
made from the EM surface peeling off during lipolysis
because the relative PL/FC ratio was higher in HDL than
in the CM+VLDL and emulsion fraction. Others also
have shown that FC transfer to HDL is a slow process: FC
increases in the HDL fraction only 5 to 8 h after a fat
meal [19] or only after 2 h incubation of HDL with VLDL
and purified rat heart LPL [36].
We have also confirmed previous studies [5] claiming
that PL transfer from TG-rich particles to human HDL is
facilitated by CETP, since its partial inhibition signifi-
cantly reduced the PL transfer (Table 3). However, hu-
man CETP expressed in the transgenic mice plasma had
no effect whatsoever on the PL transfer to mouse plasma
lipoproteins or to human HDL. This lead us to admit that
the mouse plasma PL transfer activity is so potent that
some additional protein (CETP) with PL transfer activity
would be irrelevant in an already saturated in vitro sys-
tem.
In summary, the present findings indicate unequivocally
the importance of the intravascular lipolytic mechanisms
for the PLTP and CETP facilitated PL, but not FC, trans-
fer process from TG-rich particles to HDL. PL enriched
HDL would be more efficient in promoting FC efflux
from cell membranes, hence accelerating the reverse
cholesterol transport. These may provide the basis for
the mechanism that accounts for the inverse correlation
between HDL and TG plasma levels found in epidemio-
logical studies in human populations as well as in several
circumstances where plasma lipid levels are modified by
pharmacological and dietary means.
Materials and Methods
Lipid emulsions
Cholesterol (FC), cholesteryl oleate (CO) and triolein
(TO) were obtained from NuCheck Prep (Elysian, MN,
USA) and lecithin (PL) from Lipid Products (Surrey,UK).
They were more than 99% pure as tested by thin layer
chromatography. Lipid mixtures (2% FC, 6% CO, 23%PL
and 69%TO by weight) together with 130 µCi of L-α-dio-
leoyl [1-14C]-phosphatydylcholine and 25 µCi of [1,2-
3H(N)]-cholesterol (New England Nuclear, Boston, MA,
USA) were sonicated in 2.785 M NaCl solution (d=1.101
g/ml) utilizing a Branson Cell Disruptor (Branson Ultra-
sonics Corp., Danbury, CT, USA), model B30, 1 cm
probe, with continuous output of 70-80 W, at aproxi-
mately 55°C, for 30 minutes, under N2 flow. Triglycer-
ide-rich particles were purified after discontinuous
gradient ultracentrifugation of NaCl solutions with den-
sities 1.065, 1.020 and 1.006 g/ml. A first step of 12000
rpm for 15 min in a SW41 Beckman rotor at 22°C was
performed to discard the floating coarse lipid. After re-
placing the 1.006 solution, the gradient was again centri-
fuged at 36000 rpm, for 30 min at 22°C and the
emulsion particles were recovered from the top layer.
The lipid emulsion composition achieved was: 1% FC, 4%
CO, 14% PL and 81% TO. These particles resemble native
chylomicrons [29]. By gel filtration (FPLC), 3H-FC, 14C-
PL and triglyceride co-eluted as only one peak corre-
sponding to the plasma VLDL size fraction (fractions #
13 to 17) on a HR 10/30 superose 6 column (Pharmacia
Biotech, Uppsala, Sweden).
Sources of plasma
Human blood samples from 12 fasted healthy volunteers
(5 men and 7 women, total cholesterol and triglycerides
< 200 mg/dl), were drawn on EDTA, pre (basal) and 10
min after an I.V. bolus injection of heparin (100 U/kg
BW). Male Wistar rats, approximately 300 g, had their
carotid arteries cannulated under pentobarbital anesthe-
sia. After recovery, they received saline (control) or
heparin (LPL stimulated) and after 10 min they were ex-
sanguinated on EDTA. Adult male C57Bl6 and human
CETP transgenic mice (line 5203), derived from the col-
ony of Dr AR Tall's Laboratory (Columbia University,
NY, USA) were bled with heparinized hematocrit capil-
lary tubes in the retro-orbital plexus under ketamine an-
esthesia (Vetarnacol, Konig, SP, Brazil). All plasmas
were obtained by centrifugation at 2000 rpm in a Sorval
RT6000B refrigerated centrifuge and freshly used.
Free cholesterol (FC) and phospholipid (PL) transfer assay
Control and treated plasmas (post-heparin, post-heparin
+ lipases inhibitor and control + CETP monoclonal anti-
body, TP2, provided by Dr. AR Tall) were incubated with
lipid emulsion (∼ 700 µg of triolein/ml) labeled with 3H-
FC (106 dpm/ml) and 14C-PL (2 × 105 dpm/ml) at zero
(on ice, "time zero") and for 30 minutes at 37°C. Plasma
lipoproteins were next separated by fast protein liquid
chromatography (FPLC) as described by Jiao et al. [31].
Briefly, plasma samples (200 µl) were fractionated on a
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HR 10/30 Superose 6 column (Pharmacia Biotech, Upp-
sala, Sweden) using a constant flow of 0.5 ml/min of tris-
buffered saline, pH 7.2. Sixty fractions of 0.5 ml were au-
tomatically collected. 3H- and 14C- dpm of each FPLC
fraction was determined by liquid scintilation in a beta
counter Beckman LS6000TA. As we have measured only
radioactive FC and PL, the term "transfer" is used to de-
scribe either net transfer or exchange process among LP.
Total cholesterol was also determined in the fractions
#10 to 40 by an enzymatic assay in an automatic analyzer
Cobas (F. Hoffman-La Roche, Basileia, Switzerland) us-
ing Boehringer Mannheim reagents (Mannheim, Germa-
ny).
In Vivo studies
Male Wistar rats, weighing ∼ 300 g were anesthetised
with pentobarbital ip (50 mg/Kg BW). The right carotid
artery was cannulated with a PE 50 siliconized catheter
and after laparostomy, the liver hilum was ligated. Phys-
iologic solution (control) or heparin (250 U/Kg BW) in a
final volume of 0.25 ml was injected through the carotid
catheter. After 10 minutes, labeled lipid emulsion (4 ×
105 dpm of 3H-PL and 7 × 105 dpm of 14C-FC) was inject-
ed intra-arterially. After 30 minutes, the animals were
exsanguinated by the carotid catheter and plasma lipo-
proteins were immediately separated by ultracentrifuga-
tion in a discontinuous gradient. Plasmas were adjusted
to density (d) 1.21 g/ml with solid KBr and overlayed
with solutions of d=1.063 and 1.006 g/ml and centri-
fuged for 24 h in a SW 41 rotor, at 4°C, 100000 × g, in a
L8 Beckman ultracentrifuge. Lipoproteins fractions were
collected from the top to bottom by vacuum as follow: 1.5
ml VLDL (d<1.006), 2.5 ml LDL (d = 1.006 - 1.063) and
7.5 ml HDL (d>1.063). Radioactivity was determined in
aliquots from each lipoprotein fraction.
Intravascular Lipases Activity
Total lipase activity was determined according to Ehn-
holm & Kuusi [32]. Briefly, overnight fasted human plas-
mas, collected pre (basal) and 10 minutes after heparin
I.V. injection (100 U/Kg body weight), were incubated
with a 3H-triolein/arabic gum substrate ([9,10 3H (N)]-
triolein, New England Nuclear, Boston, MA) in 0.2 M
Tris-HCl buffer, pH 8.5, 37ºC, during 1 hour. Hepatic li-
pase (HL) activity was determined in tubes where the li-
poprotein lipase (LPL) was inhibited by 2 M NaCl. The
hydrolyzed labeled free fatty acids were extracted with
methanol / chloroform / heptane (1.4 : 1.25 : 1), 0.14 M
K2CO3 / H3BO3, pH 10.5, dried under N2, and their radi-
oactivity was determined in a liquid scintillation solution
in a LS6000 Beckman Beta Counter. The LPL activity
was calculated as the difference between the total lipase
and the hepatic lipase activities.
Cholesteryl ester transfer protein activity assay
A mixture of human VLDL and LDL protein (100 µg)
were incubated with 10000 dpm of human HDL3 labeled
with [14C]-cholesteryl ester (CE) [33] and 5 µl of diluted
CETP transgenic mice plasma or undiluted human plas-
ma as the source of CETP in a final volume of 100 µl.
Blanks were prepared with tris/saline/EDTA buffer (10
mM/140 mM/1 mM), pH 7.4, and negative controls with
non-transgenic mice plasma. The incubations were car-
ried out at 37°C for 2 or 4 hours. After these periods, the
apo B containing lipoproteins were precipitated using a
mixture of 1.6% dextran sulfate / 1 M MgCl2 solution
(1:1) and the radioactivity was measured in the remain-
ing supernatant in scintillation solution Ultima Gold
(Eastman Kodak Co., NY) in a LS6000 Beckman Beta
Counter. The % CE transferred from [14C]-CE-HDL to
VLDL+LDL was calculated as: (dpm in the blank tube -
dpm in the plasma sample / dpm in the blank tube) ×
100.
Statistical analysis
All comparisons were analysed by the non-parametric
Mann-Whitney test using the GraphPad Prism, version
2.01 (1996) program. Differences were considered signif-
icant when p<0.05.
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